ClinicalTrials.Veeva

Menu

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome. ("BAC-PAC")

E

Endourage

Status

Completed

Conditions

Covid 19

Treatments

Dietary Supplement: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)

Study type

Interventional

Funder types

Industry

Identifiers

NCT04828668
ENDO-402-2021

Details and patient eligibility

About

This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".

Full description

At present, conventional medical and rehabilitation therapies have not consistently been effective for people with PACS, and in fact some symptoms have been observed to worsen over time. This inconsistency in clinical response has created a need for alternative treatment options to be explored. CBD presents a novel approach that warrants further investigation.

After review and approval by an Institutional Review Board (IRB), potential study participants will be recruited from on-line support groups who have identified themselves as persons experiencing post-acute COVID-19 syndrome also known as (long-haulers syndrome).

The study will be registered on the www.clincaltrials.gov website and will accept referrals from targeted clinics who refer their patients to the investigational site listed and individuals can also self-refer to the study center team.

Subjects will be evaluated weekly using telemedicine procedures. At completion of study, there will be a 7-day and 14-day follow up telemedicine visit to assess for continued benefit and/or re-emergence of symptoms/relapse.

Enrollment

32 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 18 years of age or older who can provide informed consent.
  2. Persons who have been diagnosed with COVID-19 and now in post-acute recovery phase.
  3. Persons who are in care with access to primary care for post COVID infection or PACS.
  4. Ability to read and write in the English language and follow study-related procedures.
  5. Ability to have mail/ study drug delivered to an address and/or P.O. Box in the recipient's name.
  6. Ability to participate in telemedicine visits/communication.
  7. If a woman of childbearing age, willing to use a dual method of contraception (barrier and/or hormonal).

Exclusion criteria

  1. Active illicit or non-prescribed drug use.
  2. Concomitant use of benzodiazepines.
  3. Concomitant use of an immune suppressant agent, e.g., prednisone.
  4. Documented history and active treatment for seizure disorder.
  5. Transaminase elevation.
  6. Active autoimmune disorder.
  7. Hepatitis C infection (currently on therapy and/or any transaminitis elevation).
  8. Hepatitis B infection (currently on therapy and/or any transaminitis elevation).
  9. Human Immune Deficiency Virus (HIV-1 or HIV-2) infection that is newly diagnosed or untreated.
  10. Any form of mental impairment that will/could hinder safe participation in the study.
  11. Pregnancy or breast-feeding.
  12. Any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

32 participants in 2 patient groups, including a placebo group

Formula C
Experimental group
Description:
30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.
Treatment:
Dietary Supplement: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Placebo
Placebo Comparator group
Description:
30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.
Treatment:
Dietary Supplement: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems